Investor Presentation for Financial Results for Quarter ended Sep 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Deccan Health Care reported strong Q2 FY26 results with standalone revenue of ₹2,440.46 lakh, up 29.7% year-on-year, and H1 revenue of ₹4,587.41 lakh, up 35.4% YoY. Net profit for the quarter rose 67.5% YoY to ₹89.97 lakh, while H1 profit grew 22.8% to ₹111.22 lakh. EBITDA jumped 136% sequentially to ₹171.08 lakh, with margins expanding to 7.0% from 3.4% on better scale and cost discipline. EPS improved sharply to ₹0.36 from ₹0.09 in the previous quarter. Management highlighted growth in the weight wellness program, functional foods like fruit bars and gummies, and export expansion with regulatory filings in 6 international markets and a UAE/GCC launch targeted for March 2026.
Positive for shareholders — strong topline growth, sharp sequential margin expansion, and a clear international expansion roadmap suggest improving fundamentals. The March 2026 UAE/GCC launch could be a future growth catalyst, though the company remains a small-cap nutraceutical player with execution risk on global plans.